Compositions and Methods for Treating Stroke

Abstract

Provided herein is a method of treating a subject believed to have suffered a stroke. This method comprises administering to the subject therapeutically effective amount of a composition comprising conivaptan or an active derivative, stereoisomer, pro-drug, or pharmaceutically acceptable salt thereof.

1 . A composition comprising a therapeutically effective amount of a chemical having the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, for treatment of a stroke in a subject. 
       
     
     
         2 . The composition of  claim 1 , wherein the treatment comprises a first administration of the composition up to 12 hours after the stroke. 
     
     
         3 . The composition of  claim 1 , wherein the treatment comprises a first administration of the composition between approximately 3 and 9 hours after the stroke. 
     
     
         4 . The composition of  claim 1 , wherein the treatment comprises a first administration of the composition between approximately 4 and 8 hours after the stroke. 
     
     
         5 . The composition of  claim 1 , wherein the treatment comprises a first administration of the composition approximately 6 hours after the stroke. 
     
     
         6 . The composition of  claim 2 , wherein the treatment comprises a continuous or intermittent administration after the first administration for up to 72 hours. 
     
     
         7 . The composition of  claim 2 , wherein the treatment comprises a continuous or intermittent administration after the first administration for up to 48 hours. 
     
     
         8 . The composition of  claim 2 , wherein the treatment comprises a continuous or intermittent administration after the first administration for up to 24 hours. 
     
     
         9 . The composition of  claim 1 , wherein the therapeutically effective amount of the composition is administered to the subject in multiple dosages, and wherein a first dosage amount of the composition is approximately 0.35 mg/kg. 
     
     
         10 . The composition of  claim 9 , wherein one or more subsequent dosage amounts are approximately 0.07 mg/kg. 
     
     
         11 . The composition of  claim 1 , further comprising a blood clot degradation compound. 
     
     
         12 . The composition of  claim 11 , wherein the blood clot degradation compound is a tissue plasminogen activator.